𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment

✍ Scribed by Regina Westmeier; Hartwig Steckel


Book ID
102400137
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
397 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


A precipitation process is used to produce combined particles consisting of two antiasthmatic drugs: salmeterol xinafoate and fluticasone propionate. To control the crystallisation of these particles, a micromixer is used to mix solvent and antisolvent flow. To produce particles in the respirable range, crystal growth inhibitors are added to the antisolvent flow. The obtained suspension is spray-dried afterwards to get a dry powder which can be further processed into inhalation drug products. It is found that a combination of polysorbate 80 and hydroxypropylmethyl cellulose (HPMC) represents the best excipient combination. It is supposed that the smaller molecule polysorbate rapidly stabilises the particle surface and with this inhibits crystal growth, whereas HPMC is observed to produce spherical particles during the spray-drying process acting as lubricant and dispersion-modifier. The processed particles show a needlelike habit and, therefore, tend to form aggregates. When dispersed from an inhaler device, they are only moderately disaggregated. The deposition of the single drugs salmeterol xinafoate and fluticasone propionate on the stages of the NGI shows a very uniform distribution, indicating that both drugs are evenly dispensed, with an FPF of about 22% for the combined particles which corresponds to the deposition of the marketed product.


πŸ“œ SIMILAR VOLUMES


Dry powder formulations for inhalation o
✍ Darragh Murnane; Gary P. Martin; Christopher Marriott πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 307 KB

Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous cryst